NasdaqCM - Delayed Quote USD

Titan Pharmaceuticals, Inc. (TTNP)

3.5900

-0.2500

(-6.51%)

At close: April 29 at 4:00:00 PM EDT

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series B Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for

GlobeNewswire 18 days ago

TTNP
-6.51%
Titan Pharmaceuticals: Q4 Earnings Snapshot

NEW YORK (AP) — Titan Pharmaceuticals Inc. TTNP) on Thursday reported a loss of $790,000 in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 85 cents.

Associated Press Finance last month

TTNP
-6.51%
Titan Pharmaceuticals: Q3 Earnings Snapshot

SAN FRANCISCO (AP) — Titan Pharmaceuticals Inc. TTNP) on Friday reported a loss of $763,000 in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss of 83 cents.

Associated Press Finance 3 months ago

TTNP
-6.51%
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today reported that it received a notice (the “5250 Notice”) on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it was not in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (“Rule 5250”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter

GlobeNewswire 4 months ago

TTNP
-6.51%
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan’s board of directors (the “Board”). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance

GlobeNewswire 8 months ago

TTNP
-6.51%
TTNPW
Titan Pharmaceuticals: Q2 Earnings Snapshot

SAN FRANCISCO (AP) — Titan Pharmaceuticals Inc. TTNP) on Thursday reported a loss of $2.1 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a loss of $2.29.

Associated Press Finance 8 months ago

TTNPW

Performance Overview

Return	TTNP	S&P 500 (^GSPC)
YTD	+10.12%	-5.45%
1-Year	-47.59%	+8.69%
3-Year	-74.36%	+34.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Titan Pharmaceuticals, Inc. (TTNP)

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

Titan Pharmaceuticals: Q4 Earnings Snapshot

Titan Pharmaceuticals: Q3 Earnings Snapshot

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

Titan Pharmaceuticals: Q2 Earnings Snapshot

Performance Overview